Zeitschrift für Rheumatologie

, Volume 73, Issue 1, pp 77–84 | Cite as

Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen Vorgehensweise unter Therapie mit DMARD und Biologicals bei entzündlich-rheumatischen Erkrankungen

  • K. Krüger
  • K. Albrecht
  • S. Rehart
  • R. Scholz
  • Kommission Pharmakotherapie der DGRh
Empfehlungen und Stellungnahmen von Fachgesellschaften

Zusammenfassung

Hintergrund

Der perioperative Einsatz antirheumatischer Arzneimittel kann zu einem erhöhten Infektionsrisiko und zu einer Wundheilungsstörung bis zum manifesten Infekt führen, andererseits kann eine Unterbrechung der antirheumatischen Therapie einen Krankheitsschub zur Folge haben. Beides kann, insbesondere in der Endoprothetik, den Operationserfolg gefährden.

Methodik

Die Empfehlungen sind vom Vorstand und der Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie nach einer systematischer Literaturrecherche (Stand 30.04.2013) und einem Konsensprozess entwickelt und verabschiedet worden.

Ergebnis

Da nur wenige Daten mit ausreichend hoher Evidenz vorhanden sind, sind die vorliegenden Empfehlungen als hinweisgebend einzuordnen. Es ist stets eine individuelle Risikoeinschätzung vorzunehmen. Klassische DMARD wie Methotrexat können im Normalfall fortgeführt werden – ob dies auch für Leflunomid gilt, ist noch umstritten. Für Biologicals wird eine Unterbrechung von zwei Halbwertszeiten vor der geplanten Operation empfohlen. Die Therapie kann nach abgeschlossener Wundheilung und bei fehlenden Zeichen einer Infektion fortgeführt werden.

Schlüsselwörter

Wundheilung Infektion Endoprothetik Konsensus Antirheumatika 

Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases

Abstract

Background

The perioperative administration of antirheumatic medication can lead to an increased risk of infection and to a malfunction in wound healing up to a manifest infection; however, the termination of antirheumatic therapy can result in a flare up of the disease. Both situations can endanger the success of the operation, particularly in arthroplasty.

Method

The recommendations have been developed and approved by the Pharmacotherapy Commission of the German Society for Rheumatology following a systematic literature search (as of 30 April 2013) and a consensus process.

Results

As very little data with sufficiently high evidence are available, the present recommendations should be considered as having an advisory quality and an individual risk assessment should always be carried out. Classical disease-modifying antirheumatic drugs (DMARD), such as methotrexate can be continued in normal cases but whether this is also true for leflunomide is still undecided. For biologicals a break of two half-life periods before the operation is recommended. The therapy can be continued after wound healing has been completed and when there are no signs of infection.

Keywords

Wound healing Infection Arthroplasty Consensus Antirheumatic agents 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. K. Krüger, K. Albrecht, S. Rehart und R. Scholz geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Pieringer H, Stuby U, Biesenbach G (2007) Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum 36:278–286PubMedCrossRefGoogle Scholar
  2. 2.
    Widmer AF (2001) New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 33(Suppl 2):S94–S106PubMedCrossRefGoogle Scholar
  3. 3.
    Ruyssen-Witrand A, Gossec L, Salliot C et al (2007) Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 25:430–436PubMedGoogle Scholar
  4. 4.
    Den Broeder AA, Creemers MC, Fransen J et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689–695Google Scholar
  5. 5.
    Bongartz T, Halligan CS, Osmon DR et al (2008) Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 59:1713–1720PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293PubMedCrossRefGoogle Scholar
  7. 7.
    Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53–61PubMedCrossRefGoogle Scholar
  8. 8.
    Jain A, Witbreuk M, Ball C, Nanchahal J (2002) Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am 27:449–455PubMedCrossRefGoogle Scholar
  9. 9.
    Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131PubMedCrossRefGoogle Scholar
  10. 10.
    Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54:628–634PubMedCrossRefGoogle Scholar
  11. 11.
    Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Dixon WG, Kezouh A, Bernatsky S, Suissa S (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 70:956–960PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Härle P, Straub RH, Fleck M (2010) Perioperative management of immunosuppression in rheumatic diseases–what to do? Rheumatol Int 30:999–1004PubMedCrossRefGoogle Scholar
  14. 14.
    Scanzello CR, Figgie MP, Nestor BJ, Goodman SM (2006) Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J 2:141–147PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Bibbo C, Anderson RB, Davis WH, Norton J (2003) The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients (corrected). Foot Ankle Int 24:40–44PubMedGoogle Scholar
  16. 16.
    Dvivedi S, Tiwari SM, Sharma A (1997) Effect of ibuprofen and diclofenac sodium on experimental would healing. Indian J Exp Biol 35:1243–1245PubMedGoogle Scholar
  17. 17.
    Visser K, Katchamart W, Loza E et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Bombardier C, Hazlewood GS, Akhavan P et al (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 39:1583–1602PubMedCrossRefGoogle Scholar
  19. 19.
    Luqmani R, Hennell S, Estrach C et al (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48:436–439Google Scholar
  20. 20.
    Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit Working Group (2005) Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44:157–163Google Scholar
  21. 21.
    Koike R, Takeuchi T, Eguchi K et al (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451–458PubMedCrossRefGoogle Scholar
  22. 22.
    Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784PubMedCrossRefGoogle Scholar
  23. 23.
    OCEBM Levels of Evidence Working Group*. „The Oxford 2011 Levels of Evidence“. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653Google Scholar
  24. 24.
    Loza E, Martinez-Lopez JA, Carmona L (2009) A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol 27:856–862PubMedGoogle Scholar
  25. 25.
    Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60:214–217PubMedCrossRefGoogle Scholar
  26. 26.
    Sany J, Anaya JM, Canovas F et al (1993) Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 20:1129–1132PubMedGoogle Scholar
  27. 27.
    Sreekumar R, Gray J, Kay P, Grennan DM (2011) Methotrexate and postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery–a ten year follow-up. Acta Orthop Belg 77:823–826PubMedGoogle Scholar
  28. 28.
    Murata K, Yasuda T, Ito H et al (2006) Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 16:14–19PubMedCrossRefGoogle Scholar
  29. 29.
    Perhala RS, Wilke WS, Clough JD, Segal AM (1991) Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 34:146–152PubMedCrossRefGoogle Scholar
  30. 30.
    Tanaka N, Sakahashi H, Sato E et al (2003) Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 9:115–118PubMedCrossRefGoogle Scholar
  31. 31.
    Fuerst M, Möhl H, Baumgärtel K, Rüther W (2006) Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 26:1138–1142PubMedCrossRefGoogle Scholar
  32. 32.
    Rehart S, Petak N (2007) Moderne rheumatische Basistherapie perioperativ. Akt Rheumatol 32:74–77CrossRefGoogle Scholar
  33. 33.
    Van Riel PLCM, Smolen JS, Emery P et al (2004) Leflunomide: a manageable safety profile. J Rheumatol 31(Suppl 71):21–24Google Scholar
  34. 34.
    Barnard AR, Regan M, Burke FD et al (2012) Wound healing with medications for rheumatoid arthritis in hand surgery. ISRN Rheumatol 2012:251962PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Escalante A, Beardmore TD (1995) Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol 22:1844–1851PubMedGoogle Scholar
  36. 36.
    Cunha BM da, Maria Henrique da Mota L, Dos Santos-Neto LL (2012) Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy. Int J Rheumatol 2012:369565PubMedCentralPubMedGoogle Scholar
  37. 37.
    Goh L, Jewell T, Laversuch C, Samanta A (2012) Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 32:5–13PubMedCrossRefGoogle Scholar
  38. 38.
    Pieringer H, Danninger K, Tzaribachev N et al (2013) Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review. Yonsei Med J 54:253–257PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Giles JT, Bartlett SJ, Gelber AC et al (2006) Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55:333–337PubMedCrossRefGoogle Scholar
  40. 40.
    Kawakami K, Ikari K, Kawamura K et al (2010) Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49:341–347Google Scholar
  41. 41.
    Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331–335PubMedGoogle Scholar
  42. 42.
    Kubota A, Nakamura T, Miyazaki Y et al (2012) Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 22:844–848PubMedCrossRefGoogle Scholar
  43. 43.
    Talwalkar SC, Grennan DM, Gray J et al (2005) Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64:650–651PubMedCrossRefGoogle Scholar
  44. 44.
    Wendling D, Balblanc JC, Brousse A et al (2005) Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 64:1378–1379PubMedCrossRefGoogle Scholar
  45. 45.
    Gilson M, Gossec L, Mariette X et al (2010) Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther 12:R145PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Pham T, Bachelez H, Berthelot JM et al (2011) TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 78(Suppl 1):15–185PubMedCrossRefGoogle Scholar
  47. 47.
    Nishida K, Nasu Y, Hashizume K et al (2013) Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol (Epub ahead of print)Google Scholar
  48. 48.
    Pham T, Bachelez H, Berthelot JM et al (2012) Abatacept therapy and safety management. Joint Bone Spine 79(Suppl 1):3–84PubMedCrossRefGoogle Scholar
  49. 49.
    Kaufmann D, Arbogast M (2010) Prä- und postoperatives Management von Patienten unter Rituximabtherapie. Akt Rheumatol 35:368–388CrossRefGoogle Scholar
  50. 50.
    Momohara S, Hashimoto J, Tsuboi H et al (2012) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol (Epub ahead of print)Google Scholar
  51. 51.
    Hirao M, Hashimoto J, Tsuboi H et al (2009) Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 68:654–657PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • K. Krüger
    • 1
  • K. Albrecht
    • 1
  • S. Rehart
    • 1
  • R. Scholz
    • 1
  • Kommission Pharmakotherapie der DGRh
  1. 1.Niedergelassener Rheumatologe, PraxiszentrumSankt-BonifatiusMünchenDeutschland

Personalised recommendations